NVAX

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company founded in 1987 and headquartered in Gaithersburg, Maryland. The company went public in 1995 and has evolved from a small biotech startup into a specialized vaccine developer focused on infectious diseases. Novavax gained significant prominence during the COVID-19 pandemic with its protein-based coronavirus vaccine, Nuvaxovid, which received regulatory approvals in multiple countries. The company has undergone a strategic transformation in recent years, transitioning from an independent vaccine manufacturer to a research and development-focused organization with a partnership-driven business model, most notably through its collaboration with pharmaceutical giant Sanofi.